Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Arcellx, Inc. - Common Stock
(NQ:
ACLX
)
52.82
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 24, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
0
Open
52.82
Bid (Size)
21.24 (1)
Ask (Size)
83.98 (1)
Prev. Close
52.82
Today's Range
52.82 - 52.82
52wk Range
30.74 - 75.10
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Peering Into Arcellx's Recent Short Interest
April 15, 2024
Via
Benzinga
Arcellx to Participate in the 23rd Annual Needham Virtual Healthcare Conference
April 04, 2024
From
Arcellx, Inc.
Via
Business Wire
Performance
YTD
-5.93%
-5.93%
1 Month
-23.26%
-23.26%
3 Month
-5.95%
-5.95%
6 Month
+63.18%
+63.18%
1 Year
+28.83%
+28.83%
More News
Read More
Arcellx to Participate at the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
March 20, 2024
From
Arcellx, Inc.
Via
Business Wire
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
March 07, 2024
Via
Benzinga
Arcellx Analysts Boost Their Forecasts After Q4 Results
February 29, 2024
Via
Benzinga
Needham Maintains Buy Rating for Arcellx: Here's What You Need To Know
January 04, 2024
Via
Benzinga
Where Arcellx Stands With Analysts
December 11, 2023
Via
Benzinga
The 3 Biotech Stocks That Could Make Your February Unforgettable
February 15, 2024
Via
InvestorPlace
Decoding Bearish Analog And The Warning Signs You Can't Ignore
February 07, 2024
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Healthcare Heroes: 3 Biotech Stocks Poised to Cure What Ails the Market
January 16, 2024
Via
InvestorPlace
Exposures
Product Safety
Blood Cancer Player Arcellx Finds Place On Analyst Conviction List - Potential Room For Growth In 2024
January 04, 2024
Via
Benzinga
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
December 15, 2023
Via
InvestorPlace
Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
December 12, 2023
Via
Benzinga
Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say
December 11, 2023
Via
Benzinga
Chart Of The Day: Arcellx - Reimagining Cell Therapy
December 08, 2023
Via
Talk Markets
3 Biotech Stocks That Could Be Multibaggers in the Making
November 30, 2023
Via
InvestorPlace
Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead
November 15, 2023
Via
Investor's Business Daily
Kite and Arcellx Announce Expansion in Strategic Partnership
November 15, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Why Is Blood Cancer Focused Arcellx Stock Trading Higher Today?
November 02, 2023
Via
Benzinga
7 Biotech Stocks to Get In Now Before Investors Catch On
October 23, 2023
Via
InvestorPlace
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
November 02, 2023
Via
Benzinga
Starbucks, Teleflex, Roku, Shopify And Other Big Stocks Moving Higher On Thursday
November 02, 2023
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs
October 02, 2023
Via
InvestorPlace
Analysts Stay Bullish On Arcellx's CART-ddBCMA's Long-term Therapeutic Potential
August 15, 2023
Via
Benzinga
Exposures
Product Safety
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
October 17, 2023
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.